Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 856815, 7 pages
http://dx.doi.org/10.1155/2013/856815
Review Article

A New ELISA for Dermatomyositis Autoantibodies: Rapid Introduction of Autoantigen cDNA to Recombinant Assays for Autoantibody Measurement

Division of Connective Tissue Disease and Autoimmunity, Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

Received 27 October 2013; Revised 19 November 2013; Accepted 19 November 2013

Academic Editor: Michael Mahler

Copyright © 2013 Yoshinao Muro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. L. Tansley, Z. E. Betteridge, and N. J. McHugh, “The diagnostic utility of autoantibodies in adult and juvenile myositis,” Current Opinion in Rheumatology, vol. 25, no. 6, pp. 772–777, 2013. View at Publisher · View at Google Scholar
  2. K. Kaji, M. Fujimoto, M. Hasegawa et al., “Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy,” Rheumatology, vol. 46, no. 1, pp. 25–28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Fujimoto, Y. Hamaguchi, K. Kaji et al., “Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins,” Arthritis and Rheumatism, vol. 64, no. 2, pp. 513–522, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Hoshino, Y. Muro, K. Sugiura, Y. Tomita, R. Nakashima, and T. Mimori, “Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis,” Rheumatology, vol. 49, no. 9, Article ID keq153, pp. 1726–1733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Muro, K. Sugiura, K. Hoshino, and M. Akiyama, “Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission,” Rheumatology, vol. 51, no. 5, Article ID ker408, pp. 800–804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Ishikawa, Y. Muro, K. Sugiura, and M. Akiyama, “Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2,” Rheumatology, vol. 51, no. 7, pp. 1181–1187, 2012. View at Publisher · View at Google Scholar
  7. S. Sato, K. Hoshino, T. Satoh et al., “RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease,” Arthritis and Rheumatism, vol. 60, no. 7, pp. 2193–2200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Cao, M. Pan, Y. Kang et al., “Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody,” Arthritis Care and Research, vol. 64, no. 10, pp. 1602–1610, 2012. View at Publisher · View at Google Scholar
  9. T. Gono, S. Sato, Y. Kawaguchi et al., “Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis,” Rheumatology, vol. 51, no. 9, pp. 1563–1570, 2012. View at Publisher · View at Google Scholar
  10. Y. Hamaguchi, M. Kuwana, K. Hoshino et al., “Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study,” Archives of Dermatology, vol. 147, no. 4, pp. 391–398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Satoh, J. Y. F. Chan, S. J. Ross et al., “Autoantibodies to Transcription Intermediary Factor (TIF)1β associated with dermatomyositis,” Arthritis Research and Therapy, vol. 14, article R79, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Muro, K. Sugiura, and M. Akiyama, “Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients,” Autoimmunity, vol. 46, no. 4, pp. 279–284, 2013. View at Publisher · View at Google Scholar
  13. Z. Betteridge, H. Gunawardena, J. North, J. Slinn, and N. McHugh, “Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis,” Arthritis and Rheumatism, vol. 56, no. 9, pp. 3132–3137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Ben-Chetrit, B. J. Gandy, E. M. Tan, and K. F. Sullivan, “Isolation and characterization of a cDNA clone encoding the 60-kD component of the human SS-A/Ro ribonucleoprotein autoantigen,” Journal of Clinical Investigation, vol. 83, no. 4, pp. 1284–1292, 1989. View at Google Scholar · View at Scopus
  15. E. K. L. Chan, H. Imai, J. C. Hamel, and E. M. Tan, “Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor,” Journal of Experimental Medicine, vol. 174, no. 5, pp. 1239–1244, 1991. View at Google Scholar · View at Scopus
  16. H. Imai, E. K. L. Chan, K. Kiyosawa, X.-D. Fu, and E. M. Tan, “Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma,” Journal of Clinical Investigation, vol. 92, no. 5, pp. 2419–2426, 1993. View at Google Scholar · View at Scopus
  17. Y. Ogawa, K. Sugiura, A. Watanabe et al., “Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain,” Journal of Autoimmunity, vol. 23, no. 3, pp. 221–231, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Hoshino, Y. Muro, K. Sugiura, Y. Tomita, R. Nakashima, and T. Mimori, “Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis,” Rheumatology, vol. 49, no. 9, Article ID keq153, pp. 1726–1733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Muro, K. Sugiura, and M. Akiyama, “Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis,” Clinical Rheumatology, vol. 32, no. 3, pp. 395–398, 2013. View at Publisher · View at Google Scholar
  20. I. N. Targoff and M. Reichlin, “The association between Mi-2 antibodies and dermatomyositis,” Arthritis and Rheumatism, vol. 28, no. 7, pp. 796–803, 1985. View at Google Scholar · View at Scopus
  21. H.-B. Wang and Y. Zhang, “Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor,” Nucleic Acids Research, vol. 29, no. 12, pp. 2517–2521, 2001. View at Google Scholar · View at Scopus
  22. H. P. Seelig, M. Renz, I. N. Targoff, Q. Ge, and M. B. Frank, “Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen,” Arthritis and Rheumatism, vol. 39, no. 10, pp. 1769–1771, 1996. View at Google Scholar · View at Scopus
  23. G. J. D. Hengstman, W. T. M. Vree Egberts, H. P. Seelig et al., “Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen,” Annals of the Rheumatic Diseases, vol. 65, no. 2, pp. 242–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. C. Parker and C. C. Bunn, “Sensitivity of the Phadia EliA connective tissue disease screen for less common disease-specific autoantibodies,” Journal of Clinical Pathology, vol. 64, no. 7, pp. 631–633, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Shimono, Y. Shimono, K. Shimokata, N. Ishiguro, and M. Takahashi, “Microspherule protein 1, Mi-2β, and RET finger protein associate in the nucleolus and up-regulate ribosomal gene transcription,” Journal of Biological Chemistry, vol. 280, no. 47, pp. 39436–39447, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Muro, K. Sugiura, and M. Akiyama, “What autoantibody tests should become widely available to help scleroderma diagnosis and management?” Arthritis Research and Therapy, vol. 15, no. 4, article 116, 2013. View at Publisher · View at Google Scholar
  27. H. A. Doyle and M. J. Mamula, “Post-translational protein modifications in antigen recognition and autoimmunity,” Trends in Immunology, vol. 22, no. 8, pp. 443–449, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. M. S. Lan, C. Wasserfall, N. K. Maclaren, and A. L. Notkins, “IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 13, pp. 6367–6370, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Xie, Y.-J. Deng, A. L. Notkins, and M. S. Lan, “Expression, characterization, processing and immunogenicity of an insulin-dependent diabetes mellitus autoantigen, IA-2, in Sf-9 cells,” Clinical and Experimental Immunology, vol. 113, no. 3, pp. 367–372, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Prentice, J. F. Sanders, M. Perez et al., “Thyrotropin (TSH) receptor autoantibodies do not appear to bind to the TSH receptor produced in an in vitro transcription/translation system,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 4, pp. 1288–1292, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. G. S. Seetharamaiah, S. Kaithamana, R. K. Desai, and B. S. Prabhakar, “Regulation of thyrotropin receptor protein expression in insect cells,” Journal of Molecular Endocrinology, vol. 23, no. 3, pp. 315–323, 1999. View at Google Scholar · View at Scopus
  32. Y. Muro, K. Sugiura, A. Shiraki et al., “Detection of autoantibodies to periplakin and envoplakin in paraneoplastic pemphigus but not idiopathic pulmonary fibrosis using full-length recombinant protein,” Clinca Chimica Acta, vol. 429, pp. 14–17, 2014. View at Publisher · View at Google Scholar
  33. M. Urh and M. Rosenberg, “HaloTag, a platform technology for protein analysis,” Current Chemical Genomics, vol. 6, pp. 72–78, 2012. View at Google Scholar